Wide Ranks

ARDX

Ardelyx, Inc.

5.69

Top Statistics
Market Cap 1 B Forward PE -33.23 Revenue Growth 74.20 %
Current Ratio 4.03 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -28.82 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -20.69 Enterprise / Revenue 5.11 Price To Sales Trailing12 Months 5.35
Profitability
Profit Margins -28.82 % Operating Margins 2.27 %
Balance Sheet
Total Cash 190 M Total Cash Per Share 0.8040 Total Debt 128 M
Total Debt To Equity 81.41 Current Ratio 4.03 Book Value Per Share 0.6680
All Measures
Short Ratio 469.00 % Message Board Id finmb_58915635 Shares Short Prior Month 22 M
Return On Equity -0.4154 City Waltham Uuid 419f5034-7b70-3f95-acd4-15f78343e65d
Previous Close 5.35 First Trade Date Epoch Utc 1 B Book Value 0.6680
Beta 0.9140 Total Debt 128 M Volume 3 M
Price To Book 8.52 Fifty Two Week Low 4.34 Total Cash Per Share 0.8040
Total Revenue 251 M Shares Short Previous Month Date 1 B Target Median Price 11.00
Audit Risk 4 Max Age 86400 Recommendation Mean 1.40
Sand P52 Week Change 0.3133 Operating Margins 2.27 % Target Mean Price 10.67
Net Income To Common -72583000 Short Percent Of Float 0.1119 Implied Shares Outstanding 236 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 4 M
Average Volume10days 4 M Total Cash 190 M Next Fiscal Year End 1 B
Revenue Per Share 1.08 Held Percent Insiders 0.0170 Ebitda Margins -24.68 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 5.35 Target Low Price 5.50
Gmt Off Set Milliseconds -18000000 Fifty Day Average 5.80 Open 5.43
Free Cashflow -6630875 State MA Dividend Yield 0.00 %
Return On Assets -0.1218 Time Zone Short Name EST Board Risk 5
Trailing Eps -0.3200 Day Low 5.32 Address1 400 Fifth Avenue
Shares Outstanding 236 M Compensation Risk 8 Price Hint 2
Target High Price 15.00 Website https://www.ardelyx.com 52 Week Change 0.2616
Average Volume 3 M Forward Eps -0.0700 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 345.50 % Is_sp_500 False
Regular Market Day High 5.72 Profit Margins -28.82 % Debt To Equity 81.41
Fifty Two Week High 10.13 Day High 5.72 Shares Short 23 M
Regular Market Open 5.43 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 5.11 Revenue Growth 74.20 % Shares Percent Shares Out 0.0984
Operating Cashflow -63337000 Currency USD Time Zone Full Name America/New_York
Market Cap 1 B Is_nasdaq_100 False Zip 02451
Quote Type EQUITY Industry Biotechnology Long Name Ardelyx, Inc.
Overall Risk 6 Regular Market Day Low 5.32 Held Percent Institutions 0.6146
Current Price 5.69 Address2 Suite 210 Enterprise To Ebitda -20.69
Financial Currency USD Current Ratio 4.03 Gross Margins 66.03 %
Industry Disp Biotechnology Number Of Analyst Opinions 9 Country United States
Float Shares 231 M Two Hundred Day Average 6.63 Governance Epoch Date 1 B
Enterprise Value 1 B Price To Sales Trailing12 Months 5.35 Forward PE -33.23
Regular Market Volume 3 M Ebitda -62151000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.

The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.

It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder.

The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co.

Ltd.

, and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories.

The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.

Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.